AR117435A1 - SUBSTITUTE OXOPYRIDINE DERIVATIVES - Google Patents
SUBSTITUTE OXOPYRIDINE DERIVATIVESInfo
- Publication number
- AR117435A1 AR117435A1 ARP190103745A ARP190103745A AR117435A1 AR 117435 A1 AR117435 A1 AR 117435A1 AR P190103745 A ARP190103745 A AR P190103745A AR P190103745 A ARP190103745 A AR P190103745A AR 117435 A1 AR117435 A1 AR 117435A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- represents hydrogen
- group
- difluoromethyl
- fluorine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas. Reivindicación 1: Compuesto caracterizado porque es de formula (1), en la cual R¹ representa metilo, etilo, difluorometilo o trifluorometilo, R² representa hidrógeno, metilo, difluorometilo o trifluorometilo, o R¹ y R² junto con los átomos de carbono a los cuales están unidos forman un anillo de ciclobutilo, R³ representa metilo, etilo o n-propilo, donde el metilo puede estar sustituido con un sustituyente seleccionado entre el grupo que consiste en ciclopropilo, ciclobutilo, oxetan-2-ilo, oxetan3-ilo, tetrahidrofuran-2-ilo, tetrahidro-2H-piran-2-ilo, tetrahidro-2H-piran-4-ilo y 1,4-dioxan-2-ilo, donde el oxetan-2-ilo, tetrahidrofuran-2-ilo, tetrahidro-2H-piran-2-ilo y 1,4-dioxan-2-ilo pueden estar sustituidos por 1 a 2 sustituyentes independientemente entre sí seleccionados entre el grupo que consiste en flúor y metilo, o donde el metilo puede estar sustituido con un sustituyente del grupo de la fórmula seleccionada del grupo de fórmulas (2), donde * es el sitio de unión al grupo metilo, R⁹ representa metilo, etilo, iso-propilo, ciclopropilo, difluorometilo o trifluorometilo, R¹⁰ representa metilo o difluorometilo, y donde el etilo puede estar sustituido con un sustituyente seleccionado entre el grupo que consiste en metoxi, etoxi, iso-propoxi, ter-butoxi, difluorometoxi, trifluorometoxi, 2,2-difluoroetoxi, 2,2,2-trifluoroetoxi, ciclopropiloxi y ciclobutiloxi, donde el ciclopropiloxi y el ciclobutiloxi pueden estar sustituidos con un sustituyente seleccionado entre el grupo que consiste en flúor y metilo, R⁴ representa hidrógeno, R⁵ representa un grupo de la fórmula seleccionada del grupo de fórmulas (3), donde # es el sitio de unión al átomo de nitrógeno, R¹¹ representa hidrógeno o flúor, R¹² representa metilo, difluorometilo o trifluorometilo, R¹³ representa metilo, difluorometilo o trifluorometilo, R¹⁴ representa hidrógeno o metilo, R¹⁵ representa hidrógeno o metilo, R¹⁶ representa hidrógeno o metilo, R¹⁷ representa hidrógeno o metilo, R⁶, R⁷ y R⁸ representan lo siguiente: R⁶ representa hidrógeno, flúor o cloro, R⁷ representa hidrógeno, R⁸ representa hidrógeno, o R⁶ representa hidrógeno, R⁷ representa flúor o cloro, R⁸ representa hidrógeno, o R⁶ representa hidrógeno, R⁷ representa hidrógeno, R⁸ representa flúor, o una de las sales del mismo, solvatos del mismo, o solvatos de las sales del mismo.Its use to prepare medicaments for the treatment and / or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and / or thrombotic or thromboembolic complications. Claim 1: Compound characterized in that it is of formula (1), in which R¹ represents methyl, ethyl, difluoromethyl or trifluoromethyl, R² represents hydrogen, methyl, difluoromethyl or trifluoromethyl, or R¹ and R² together with the carbon atoms to which they are together they form a cyclobutyl ring, R³ represents methyl, ethyl or n-propyl, where methyl may be substituted with a substituent selected from the group consisting of cyclopropyl, cyclobutyl, oxetan-2-yl, oxetan3-yl, tetrahydrofuran-2 -yl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-4-yl and 1,4-dioxan-2-yl, where oxetan-2-yl, tetrahydrofuran-2-yl, tetrahydro-2H -pyran-2-yl and 1,4-dioxan-2-yl may be substituted by 1 to 2 substituents independently of each other selected from the group consisting of fluorine and methyl, or where methyl may be substituted with a substituent from the group of the formula selected from the group of formulas (2), where * is the binding site to the methyl group lo, R⁹ represents methyl, ethyl, iso-propyl, cyclopropyl, difluoromethyl, or trifluoromethyl, R¹⁰ represents methyl or difluoromethyl, and where ethyl may be substituted with a substituent selected from the group consisting of methoxy, ethoxy, iso-propoxy, ter -butoxy, difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, cyclopropyloxy and cyclobutyloxy, where cyclopropyloxy and cyclobutyloxy may be substituted with a substituent selected from the group consisting of fluorine and methyl, R⁴ represents hydrogen, R⁵ represents a group of the formula selected from the group of formulas (3), where # is the site of attachment to the nitrogen atom, R¹¹ represents hydrogen or fluorine, R¹² represents methyl, difluoromethyl or trifluoromethyl, R¹³ represents methyl, difluoromethyl or trifluoromethyl, R¹⁴ represents hydrogen or methyl, R¹⁵ represents hydrogen or methyl, R¹⁶ represents hydrogen or methyl, R¹⁷ represents hydrogen or methyl, R⁶, R⁷ and R⁸ represent the R⁶ represents hydrogen, fluorine or chlorine, R⁷ represents hydrogen, R⁸ represents hydrogen, or R⁶ represents hydrogen, R⁷ represents fluorine or chlorine, R⁸ represents hydrogen, or R⁶ represents hydrogen, R⁷ represents hydrogen, R⁸ represents fluorine, or one of the salts thereof, solvates thereof, or solvates of salts thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117435A1 true AR117435A1 (en) | 2021-08-04 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103745A AR117435A1 (en) | 2018-12-21 | 2019-12-18 | SUBSTITUTE OXOPYRIDINE DERIVATIVES |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (en) |
| JP (1) | JP2022514303A (en) |
| KR (1) | KR20210106504A (en) |
| CN (1) | CN113474348A (en) |
| AR (1) | AR117435A1 (en) |
| AU (1) | AU2019407909B2 (en) |
| BR (1) | BR112021009435A2 (en) |
| CA (1) | CA3124220A1 (en) |
| CL (1) | CL2021001613A1 (en) |
| CO (1) | CO2021007908A2 (en) |
| CR (1) | CR20210342A (en) |
| DO (1) | DOP2021000128A (en) |
| EA (1) | EA202191764A1 (en) |
| EC (1) | ECSP21043895A (en) |
| IL (1) | IL283990A (en) |
| JO (1) | JOP20210161A1 (en) |
| MA (1) | MA54521A (en) |
| MX (1) | MX2021007508A (en) |
| PE (1) | PE20211790A1 (en) |
| SG (1) | SG11202104384PA (en) |
| TW (1) | TW202039510A (en) |
| WO (1) | WO2020127504A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018562A2 (en) * | 2018-03-15 | 2020-12-29 | Bayer Aktiengesellschaft | PREPARATIVE PROCESS |
| CN114105881B (en) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | Platelet aggregation inhibitor, and preparation method and application thereof |
| US20240174633A1 (en) | 2021-03-09 | 2024-05-30 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CR20230431A (en) | 2021-03-09 | 2023-10-27 | Bayer Ag | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| CN114560754A (en) * | 2022-02-25 | 2022-05-31 | 滁州学院 | Preparation method of alkyl alcohol |
| WO2024223790A1 (en) * | 2023-04-28 | 2024-10-31 | Basf Se | Use of alkyl 4-alkoxypentanoates as aroma chemicals |
| CN116874469B (en) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | Oxo-pyridine compound, intermediate, preparation method and application thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (en) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituted indazoles |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (en) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | Substituted oxopyridine derivatives |
| CN105555767B (en) | 2013-07-23 | 2018-03-23 | 拜耳制药股份公司 | Substituted oxo pyridine derivative and its purposes as factor XI, plasma thromboplastin antecedent A/ blood plasma |
| WO2015063093A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| EP3197889B1 (en) | 2014-09-24 | 2018-08-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| EP3197873B1 (en) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046158A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2722425T3 (en) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | (2H) -2-Oxopyridines as inhibitors of factor XIa for the treatment of thrombotic diseases |
| EP3197891B1 (en) * | 2014-09-24 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| ES2716417T3 (en) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivatives of oxopyridine substituted with anti-inflammatory and antithrombotic action |
| US20190119213A1 (en) | 2015-03-19 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (en) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | Substituted oxopyridine derivatives |
| EP3344618A1 (en) | 2015-09-04 | 2018-07-11 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
-
2019
- 2019-12-18 AR ARP190103745A patent/AR117435A1/en unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/en unknown
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en active Application Filing
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/en active Pending
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/en not_active Application Discontinuation
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 MA MA054521A patent/MA54521A/en unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/en unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/en unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/en unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/en unknown
- 2019-12-18 TW TW108146372A patent/TW202039510A/en unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/en active Pending
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/en active Search and Examination
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/en unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/en unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/en unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019407909B2 (en) | 2023-05-25 |
| CA3124220A1 (en) | 2020-06-25 |
| CL2021001613A1 (en) | 2021-12-03 |
| KR20210106504A (en) | 2021-08-30 |
| BR112021009435A2 (en) | 2021-08-17 |
| PE20211790A1 (en) | 2021-09-09 |
| TW202039510A (en) | 2020-11-01 |
| MA54521A (en) | 2022-03-30 |
| ECSP21043895A (en) | 2021-07-30 |
| CR20210342A (en) | 2021-08-09 |
| AU2019407909A1 (en) | 2021-05-27 |
| SG11202104384PA (en) | 2021-05-28 |
| DOP2021000128A (en) | 2021-09-30 |
| CN113474348A (en) | 2021-10-01 |
| IL283990A (en) | 2021-07-29 |
| JP2022514303A (en) | 2022-02-10 |
| MX2021007508A (en) | 2021-08-05 |
| EA202191764A1 (en) | 2021-10-22 |
| CO2021007908A2 (en) | 2021-07-19 |
| JOP20210161A1 (en) | 2023-01-30 |
| EP3898633A1 (en) | 2021-10-27 |
| WO2020127504A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117435A1 (en) | SUBSTITUTE OXOPYRIDINE DERIVATIVES | |
| AR098492A1 (en) | PURINA DERIVATIVES | |
| AR111776A1 (en) | HETEROARILOS INHIBITORS OF THE RUT MUTANT PROTEINS OF G12C | |
| AR107488A1 (en) | BENZOPIRAZOL COMPOUNDS AND THESE ANALOGS | |
| AR105104A1 (en) | HYDROXYACID DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| AR096643A1 (en) | SYNTHESIS PROCEDURE FOR THE PREPARATION OF MACROCYCLIC ANALOGS C1-CHALET OF HALICONDRINE B AND USEFUL INTERMEDIARIES IN THE SAME INCLUDING INTERMEDIARIES CONTAINING GROUPS -SO₂- (P-TOLILO) | |
| AR111241A1 (en) | FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS | |
| AR087901A1 (en) | DIHYDROQUINOLINE-2-ONA DERIVATIVES AS INHIBITORS OF ALDOSTERONE SYNTHEASE AND PROCEDURE FOR OBTAINING | |
| AR100886A1 (en) | 3-AMINO-1,5,6,7-TETRAHIDRO-4H-INDOL-4-ONAS | |
| AR093036A1 (en) | PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS | |
| AR112099A1 (en) | SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES AND THEIR USE | |
| AR112907A1 (en) | PYRAZOLES INHIBITORS OF MONOACYLGLICEROL LIPASE (MAGL) | |
| AR090678A1 (en) | DERIVATIVES OF PHENYL-TETRAHYDROISOQUINOLINE AS INHIBITORS OF ALDOSTERONA-SINTASA AND A METHOD FOR SYNTHESIS | |
| AR100879A1 (en) | DERIVATIVES OF INDOLIZINE AS INHIBITORS OF PHOSFOINOSITIDO-3 KINASES | |
| AR113888A1 (en) | SUBSTITUTE MACROCYCLIC INDOLE DERIVATIVES | |
| AR103266A1 (en) | REPLACED CYCLIC COMPOUNDS WITH A CONDENSED RING SYSTEM TO COMBAT INVERTEBRATE PESTS | |
| AR104856A1 (en) | DIFLUOROCETAMIDE DERIVATIVES | |
| AR101077A1 (en) | TRITERPENOIDS WITH INHIBITING ACTIVITY OF HIV MATURATION | |
| AR103192A1 (en) | ISOTIAZOLAMIDS, PROCESSES FOR THEIR PREPARATION AND ITS USE AS HERBICIDES AND / OR REGULATORS OF VEGETABLE GROWTH | |
| AR112086A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | |
| AR097403A1 (en) | BENZAMIDE DERIVATIVES AS AN LPG1 AND / OR LPAR5 ANTAGONISTS AND A PROCESS FOR THEIR PREPARATION | |
| AR097754A1 (en) | SUBSTITUTED DERIVATIVES OF PHENYLALANINE | |
| AR096424A1 (en) | COMPOUNDS OF 3,4-DIHIDRO-2H-ISOQUINOLIN-1-ONA AND 2,3-DIHIDRO-ISOINDOL-1-ONA | |
| AR107512A1 (en) | TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS | |
| AR124222A1 (en) | CONDENSED HETEROCYCLIC DERIVATIVES |